FDA Orders Singulair Inhaler To Carry Black Box For Behavior, Mood Changes
SILVER SPRING, Md. — The Food and Drug Administration on March 4 ordered a black box warning about serious behavior and mood-related risks for Singulair-brand montelukast, an inhaler first approved 22...To view the full article, register now.
Already a subscriber? Click here to view full article